Sugi Predict

Sugi Predict / Compounds / SCHEMBL1615552

SCHEMBL1615552

SCHEMBL1615552

O=C(NS)Nc1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.73
▸ TP53 P04637 1/20 0.73
▸ EPHX1 P07099 1/20 0.73
▸ TSHR P16473 1/20 0.73
▸ EPHX2 P34913 1/20 0.73
▸ CDK9 P50750 1/20 0.73
▸ CLK4 Q9HAZ1 1/20 0.73
▸ CASP3 P42574 1/20 0.61
▸ SENP7 Q9BQF6 1/20 0.61
▸ MAOA P21397 2/20 0.59
▸ MAOB P27338 2/20 0.59
▸ RAB9A P51151 5/20 0.57
▸ KMT2A Q03164 5/20 0.57
▸ NPC1 O15118 4/20 0.57
▸ TAAR1 Q96RJ0 3/20 0.57
▸ MEN1 O00255 3/20 0.55
▸ ACP1 P24666 2/20 0.55
▸ SIRT1 Q96EB6 1/20 0.55
▸ NAPRT Q6XQN6 1/20 0.54
▸ HSD17B10 Q99714 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diphenylurea SCHEMBL133103 0.85 SMN1; SMN2 (1.00) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL11059378 0.82 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL28431956 0.82 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL3037927 0.82 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL29392345 0.82 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL30786615 0.82 SMN1; SMN2 (0.94) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL28742998 0.80 EPHX2 (0.58) SMN1; SMN2TP53TSHREPHX2RAB9A
SCHEMBL10401175 0.80 SMN1; SMN2 (0.80) SMN1; SMN2TP53EPHX1TSHREPHX2
Diphenylurea SCHEMBL11596319 0.79 SMN1; SMN2 (0.77) SMN1; SMN2TP53EPHX1TSHREPHX2
SCHEMBL11699912 0.79 MAOA (0.63) SMN1; SMN2TP53EPHX1TSHREPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106414458-B Novel fused imidazobenzothiazole compounds TORRENT PHARMACEUTICALS LTD. (IN) 2019-10-29 — — CN claimed
CN-106414458-A Novel fused imidazobenzothiazole compounds 托伦特药物有限公司 2017-02-15 — — CN claimed
EP-2176238-A1 MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K AstraZeneca AB (SE) 2010-04-21 — — EP claimed
WO-2009007750-A1 MORPHOLINO PYRIMIDINE DERIVATIVES USED IN DISEASES LINKED TO MTOR KINASE AND/OR PI3K ASTRAZENECA AB (SE) 2009-01-15 — — WO claimed
US-6767906-B2 INHIBIT P34CDC2/CYCLIN BCDC13 KINASE AND PROTEIN TYROSINE KINASE PP60C-SRC AND CAN BE USED FOR TREATMENT OF HYPERPROLIFERATIVE DISEASES, FOR EXAMPLE CHEMOTHERAPY OF TUMOURS OR OSTEOPOROSIS. NOVARTIS AG (CH) 2004-07-27 — — US claimed
EP-1153024-B1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2004-04-28 — — EP claimed
EP-0874846-B1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 2003-04-02 — — EP claimed
JP-2002537300-A — — 2002-11-05 — — JP claimed
CN-1340054-A 2-amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-03-13 — — CN claimed
US-20020016329-A1 2-Amino-6-anilino-purines and their use as medicaments NOVARTIS AG (CH) 2002-02-07 — — US claimed
EP-1153024-A1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS Novartis AG (CH) 2001-11-14 — — EP claimed
CN-1066147-C Purine derivatives and process for preparing same 诺瓦提斯公司 2001-05-23 — — CN claimed
WO-2000069815-A1 UREIDO-SUBSTITUTED CYCLIC AMINE DERIVATIVES AND THEIR USE AS DRUG TEIJIN LIMITED (JP) 2000-11-23 — — WO claimed
WO-2000049018-A1 2-AMINO-6-ANILINO-PURINES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2000-08-24 — — WO claimed
CN-1202896-A Purine derivatives and processes for their preparation 诺瓦提斯公司 1998-12-23 — — CN claimed
EP-0874846-A1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION Novartis AG (CH) 1998-11-04 — — EP claimed
WO-1997016452-A1 PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION NOVARTIS AG (CH) 1997-05-09 — — WO claimed
EP-0292438-B1 Functional fluids FMC CORP UK LTD (GB) 1994-11-30 — — EP claimed
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-10-30 — — US disclosed
EP-0123254-A1 Triazine derivatives, processes for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1984-10-31 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016329-A1 2-Amino-6-anilino-purines and their use as medicaments CDK14, CDK1, CCNB1 SMN1; SMN2 3626/4885TP53 192/4885EPHX1 3337/4885
US-20250333385-A1 DIARYLHYDANTOIN COMPOUNDS BPHL, AR, SHBG SMN1; SMN2 4875/4885TP53 519/4885EPHX1 249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.